NCT01688466View on ClinicalTrials.gov

Pomalidomide for Chronic Graft-versus-Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 30, 2012

Primary Completion Date

March 30, 2017

Study Completion Date

May 20, 2019

Conditions
Graft vs Host DiseaseGraft-Versus-Host Disease
Interventions
DRUG

Pomalidomide

0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01688466 - Pomalidomide for Chronic Graft-versus-Host Disease | Biotech Hunter | Biotech Hunter